Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 4/20 | 0.81 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.81 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.81 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroquinine SCHEMBL109600 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinine SCHEMBL109601 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL22754573 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL25429627 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL109603 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL23509584 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL109602 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL25429352 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL22754576 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A | |
| Hydroquinidine SCHEMBL308962 | 1.00 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1HSD17B10ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564688-A | Application of quinidine hydride in preparation of medicine for treating migraine | 武汉大学人民医院（湖北省人民医院） | 2025-03-07 | — | — | CN | claimed |
| WO-2023230770-A1 | METHODS OF LUNG ADENOCARCINOMA TREATMENT WITH NON ANTI-LUAD DRUGS OR COMPOUNDS | Suzhou Singleron Biotechnologies Co., Ltd. (CN) | 2023-12-07 | — | — | WO | claimed |
| WO-2023177376-A2 | THE USE OF THE MOLECULE HYDROQUINIDINE IN THE TREATMENT OF BRAIN TUMORS | MUGLA SITKI KOCMAN UNIVERSITESI IDARI MALI ISLER BASKANLIGI (TR) | 2023-09-21 | — | — | WO | claimed |
| CN-115919857-A | Application of hydrogenated quinidine as single active ingredient in preparation of antitumor drugs | 新疆前进荣耀投资有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115651053-A | Preparation method of 3 alpha-5-cyclo-5 alpha-ergosta-22-ene-6-ketone | 广东五洲药业有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-11554106-B2 | Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin | CHILDS, MARC (FR) | 2023-01-17 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20210052549-A1 | PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN | CHILDS MARC (FR) | 2021-02-25 | — | — | US | claimed |
| EP-3774721-A1 | SYNTHESIS OF (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE AND DERIVATIVES | Heidelberg Pharma Research GmbH (DE) | 2021-02-17 | — | — | EP | claimed |
| EP-3747886-A1 | DERIVATIVES OF HYDROCINCHONINE, HYDROQUININE AND HYDROQUINIDINE, METHOD FOR THE PREPARATION THEREOF AND USE THEREOF AS CATALYSTS OF PTC PROCESSES | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2020-12-09 | — | — | EP | claimed |
| US-6387033-B1 | CIS ISOMERS FOR HYDROXYLATION OF OLEFINS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-05-14 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5962724-A | FROM THE CORRESPONDING MESODICARBOXYLIC ACID ANHYDRIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | claimed |
| EP-0776905-A2 | Process for the preparation of (24R)-24,25-dihydroxysteroid compounds | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-06-04 | — | — | EP | claimed |
| US-5635515-A | ADMINISTERING CINCHONINE AND/OR HYDROQUINIDINE | DEBIOPHARM S.A. (CH) | 1997-06-03 | — | — | US | claimed |
| CN-1138850-A | Novel high enantio-selective process for producing pure enantiomeric cyclopentane and cyclopentene-'beta'-amino acids | BAYER AG (DE) | 1996-12-25 | — | — | CN | claimed |
| EP-0526608-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS. | DEBIOPHARM SA (CH) | 1993-02-10 | — | — | EP | claimed |
| WO-1992014467-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS | DEBIOPHARM S.A. (CH) | 1992-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052549-A1 | PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN | TXN2, ABAT, ACAT1 | CYP2D6 606/4885KDM4E 2809/4885ALDH1A1 380/4885 |
| US-11554106-B2 | Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin | TXN2, ABAT, ACAT1 | CYP2D6 606/4885KDM4E 2809/4885ALDH1A1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.